Industry trends in antibody partnering – 2007 to 2013

currentpartnering

Blogged on behalf of Current Partnering, Wildwood Ventures

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent deal making activity. An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by B-cells that is used by the immune system to identify and neutralize foreign objects such as bacteria and viruses.

According to the Current Agreements life science deals and alliance database, around 1,000 antibody partnering deals were announced since 2007. The Antibody Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals covering the following types of antibodies:

  • Antibody-drug conjugates
  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb
  • Polyclonal Antibodies

Download this article to find out more about antibody dealmaking trends between 2007 and 2013  >

Leave a Reply

Your email address will not be published. Required fields are marked *